structures at interfaces including water-soluble polymers and receptor-mediated cell adhesion. His honors include the F. I. R. S. T. Award from the National Institutes of Health, the Alfred M. Hunt Faculty Scholarship, the NATO/SERC (England) Fellowship, and the Oppenheimer Research Fellowship.
V. Adrian Parsegian is chief of the Laboratory of Physical and Structural Biology at the National Institute of Child Health and Human Development. He received an A.B. in physics from Dartmouth College and a Ph.D. in biophysics from Harvard University. His research has provided fundamental contributions to the study of intermolecular forces in biological systems through measuring, formulating, computing, and gauging the consequences of forces that organize biomolecules. His work has included the theory and measurement of intermolecular forces, ion transport across cell membranes, protein conformation, colloids, aqueous interfaces, liquid crystals of lipids, protein, and nucleic acids. He is a fellow of the Biophysical Society and its former president, and he received the Society’s Distinguished Service Award in 1995. He is also the recipient of the NIH Director’s Award, which is NIH’s highest award. He has just published a book, Van der Waals Forces: A Handbook for Biologists, Chemists, Engineers, and Physicists, the first of an intended series of texts to make the physics of intermolecular forces accessible to those without a background in advanced physics.
Alan Rudolph is president and CEO of Adlyfe, Inc. Dr. Rudolph has led R&D programs in biological self-assembly for over 20 years. He is currently spearheading an effort to develop novel technologies in the private sector as an active CEO of a small biotechnology start-up, and nurture emerging technologies through his consulting practice and board positions on foundations. Prior to this assignment, Dr. Rudolph was chief of biological sciences for the Defense Sciences Office at DARPA, where he managed a $40 million life sciences portfolio in academia and industry, focusing on early risk reduction in the context of prototype development and technology transfer. His position at DARPA was to invest and manage high-risk, high-payoff multidisciplinary R&D projects in biotechnology. These programs included the design and fabrication of useful interfaces for biological molecules, cells, and tissues for working devices (e.g., diagnostics, sensors, prosthetics). He has also explored the development of wireless devices with biological systems in order to better understand and develop emerging technologies. Dr. Rudolph is the author of 100 technical publications, including seminal work in Nature and at the National Academy of Sciences and holds 15 patents, of which 2 are licensed for commercial development (drug delivery and medical imaging). He received his B.S. with highest honors in biology from the University of Michigan, a Ph.D. in cell biology from the University of California, and an M.B.A from the George Washington University.